The cancer anorexia-cachexia syndrome: myth or reality?
- PMID: 19937260
- DOI: 10.1007/s00520-009-0772-6
The cancer anorexia-cachexia syndrome: myth or reality?
Abstract
Background: Controversy exists as what constitutes the cancer anorexia-cachexia syndrome (CACS), and whether it truly is a distinct clinical disorder. In this study, we aimed to: (1) assess if CACS is a distinct clinical disorder, (2) identify the symptoms characteristic of CACS, (3) evaluate CACS impact on patient outcomes (symptom burden and survival time from referral).
Methods: Consecutive patients referred to palliative medicine were assessed by 38-symptom questionnaire. Demographics, Eastern Cooperative Oncology Group (ECOG), disease and extent, and survival were recorded. CACS, defined as anorexia plus weight loss (>10% of pre-illness weight). For analysis, patients were divided into four groups: (1) group CACS; (2) group A (only anorexia, NO >10% pre-illness weight loss); (3) group WL (weight loss >10% pre-illness weight only but NO anorexia); and (4) group N (NO weight loss >10% pre-illness weight and NO anorexia). Symptoms present in > or =5%, and patients with complete data were analyzed.
Results: Four hundred eighty-four patients had complete data, metastatic cancer, and 26 symptoms present in > or =5%. Groups had significantly different ECOG, symptom burden, and survival. Significantly different symptom prevalence between groups: dry mouth,*early satiety,*constipation,*nausea,*taste changes,*vomiting,*dysphagia,*fatigue,*weak,*lack of energy, insomnia, dyspnea, depression, hoarseness, and anxiety. The nine symptoms with asterisk were CACS specific. Symptom Burden: CACS independently predicted greatest burden. Survival: Group N had significantly longer survival.
Conclusions: CACS appeared to be a distinct disorder with unique clinical characteristics in our advanced cancer population. Nine other symptoms constituted CACS. CACS independently predicted higher symptom burden. CACS absence predicted longer survival. More evidence is needed to better characterize this syndrome and generate a valid CACS consensus. A comprehensive validated CACS assessment instrument is required.
Similar articles
-
Differences in Symptom Burden Among Cancer Patients With Different Stages of Cachexia.J Pain Symptom Manage. 2017 May;53(5):919-926. doi: 10.1016/j.jpainsymman.2016.12.325. Epub 2017 Jan 3. J Pain Symptom Manage. 2017. PMID: 28062340
-
Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.J Pain Symptom Manage. 2015 Apr;49(4):680-9. doi: 10.1016/j.jpainsymman.2014.09.008. Epub 2014 Nov 4. J Pain Symptom Manage. 2015. PMID: 25461669
-
Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS).Support Care Cancer. 2015 Aug;23(8):2341-7. doi: 10.1007/s00520-015-2606-z. Epub 2015 Jan 14. Support Care Cancer. 2015. PMID: 25586527
-
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).Clin Transl Oncol. 2024 Nov;26(11):2866-2876. doi: 10.1007/s12094-024-03502-8. Epub 2024 Jun 1. Clin Transl Oncol. 2024. PMID: 38822976 Free PMC article. Review.
-
Cancer anorexia - cachexia syndrome.Acta Med Indones. 2012 Apr;44(2):154-62. Acta Med Indones. 2012. PMID: 22745148 Review.
Cited by
-
Nutritional Status and Feeding Regimen of Patients with Esophagus Cancer-A Study from Vietnam.Healthcare (Basel). 2021 Mar 6;9(3):289. doi: 10.3390/healthcare9030289. Healthcare (Basel). 2021. PMID: 33800823 Free PMC article.
-
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.Cancer. 2019 Dec 1;125(23):4294-4302. doi: 10.1002/cncr.32406. Epub 2019 Aug 15. Cancer. 2019. PMID: 31415709 Free PMC article.
-
The influence of different muscle mass measurements on the diagnosis of cancer cachexia.J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):615-622. doi: 10.1002/jcsm.12200. Epub 2017 Apr 26. J Cachexia Sarcopenia Muscle. 2017. PMID: 28447434 Free PMC article.
-
Effects of Serum Leptin and Resistin Levels on Cancer Cachexia in Patients With Advanced-Stage Non-Small Cell Lung Cancer.Clin Med Insights Oncol. 2017 Feb 20;11:1179554917690144. doi: 10.1177/1179554917690144. eCollection 2017. Clin Med Insights Oncol. 2017. PMID: 28469508 Free PMC article.
-
Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.Support Care Cancer. 2013 Jan;21(1):129-37. doi: 10.1007/s00520-012-1500-1. Epub 2012 Jun 16. Support Care Cancer. 2013. PMID: 22699302 Clinical Trial.
References
MeSH terms
LinkOut - more resources
Full Text Sources